News & Updates

Show Multimedia Only

Enfortumab vedotin-pembrolizumab beats chemo as 1L Tx for bladder cancer

03 Nov 2023 by

In the phase III EV-302/KEYNOTE-A39 trial, the combination of enfortumab vedotin and pembrolizumab (EV+P) had a significant survival advantage over chemotherapy in the first-line treatment of patients with locally advanced metastatic urothelial carcinoma (la/mUC).

03 Nov 2023

Biomarker-driven therapies superior to standard care in breast cancer

02 Nov 2023

Patients with breast cancer may gain greater therapeutic advantages from biomarker-driven than standard-of-care therapies, suggests a study.

02 Nov 2023

Single-nucleotide variants linked to doxorubicin pharmacokinetics

01 Nov 2023

Several factors are directly associated with either an increase or a decrease of pharmacokinetic parameters of doxorubicin, reports a recent study.

01 Nov 2023

4-hydroxytamoxifen gel strikes out in ductal carcinoma in situ lesions

27 Oct 2023

Local transdermal therapy with 4-hydroxytamoxifen appears to be less effective than full-dose oral tamoxifen in terms of suppressing proliferation in ductal carcinoma in situ lesions for breast cancer prevention, according to a phase II study.

27 Oct 2023

Histologic margin status predicts relapse in lentigo maligna melanoma

26 Oct 2023

Histologic margin status shows a robust association with progression for lentigo maligna melanoma, suggest the results of a recent study.

26 Oct 2023

Brentuximab vedotin fares well for CTCL in real-world study

26 Oct 2023 by

Interim findings from a prospective real-world study in Poland demonstrated favourable clinical outcomes and a tolerable safety profile for the CD30-directed antibody-drug conjugate brentuximab vedotin in patients with CD30-expressing cutaneous T-cell lymphoma (CTCL).

26 Oct 2023

Niraparib tied to more toxicities than olaparib in ovarian cancer

25 Oct 2023

Use of niraparib appears to contribute to a higher risk of haematological toxicities as compared with olaparib, suggests a study. The most common haematological adverse event is anaemia.

25 Oct 2023

$Anlotinib shows promise for radioiodine-refractory differentiated thyroid carcinoma$

Anlotinib shows promise for radioiodine-refractory differentiated thyroid carcinoma

20 Oct 2023

The multikinase inhibitor anlotinib appears to have promising antitumour activity in the treatment of locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma while having an acceptable safety profile, as shown in a phase II study.

20 Oct 2023

First-line therapies for advanced NSCLC improve survival, QoL

16 Oct 2023

Clinical trials on first-line therapies for advanced or metastatic nonsmall cell lung cancer (NSCLC) from 2010 to 2020 have reported better survival and a steady improvement in quality of life (QoL) among patients, according to the results of a systematic review.

16 Oct 2023

Behavioural interventions improve screening colonoscopy uptake

16 Oct 2023 by

Use of behavioural interventions, specifically multicomponent and patient navigation interventions, helps increase the uptake of colonoscopy for colorectal cancer (CRC) screening, reveals a study.

16 Oct 2023

News & Updates

Showing Oncology articles

Showing

Specialty:

Enfortumab vedotin-pembrolizumab beats chemo as 1L Tx for bladder cancer

Biomarker-driven therapies superior to standard care in breast cancer

Single-nucleotide variants linked to doxorubicin pharmacokinetics

4-hydroxytamoxifen gel strikes out in ductal carcinoma in situ lesions

Histologic margin status predicts relapse in lentigo maligna melanoma

Brentuximab vedotin fares well for CTCL in real-world study

Niraparib tied to more toxicities than olaparib in ovarian cancer

Anlotinib shows promise for radioiodine-refractory differentiated thyroid carcinoma

First-line therapies for advanced NSCLC improve survival, QoL

Behavioural interventions improve screening colonoscopy uptake